Orchard Therapeutics (Nasdaq:ORTX) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ORTX Panoramica delle azioni

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.

Informazioni sull'azienda

ORTX analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 34.51% all'anno

Gli utili sono cresciuti del 12.3% all'anno negli ultimi 5 anni

Analisi del rischio

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Ha meno di 1 anno di pista di cassa

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Orchard Therapeutics plc Concorrenti

Artiva Biotherapeutics

NasdaqGM:ARTV

US$340.3m

Foghorn Therapeutics

NasdaqGM:FHTX

US$517.9m

Adaptimmune Therapeutics

NasdaqGS:ADAP

US$249.9m

AC Immune

NasdaqGM:ACIU

US$371.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Orchard Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$16.70
Massimo di 52 settimane	US$16.72
Minimo di 52 settimane	US$4.24
Beta	0.55
1Variazione di 1 mese	1.71%
Variazione a 3 mesi	4.57%
Variazione di 1 anno	188.88%
3Variazione a 3 anni	-70.28%
Variazione a 5 anni	-86.41%
Variazione dall'IPO	-88.07%

Notizie e aggiornamenti recenti

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

Rendimenti per gli azionisti

	ORTX	US Biotechs	US Mercato
7D	0.9%	-2.8%	0.7%
1Y	188.9%	19.3%	32.3%

Ritorno vs Industria: ORTX ha superato il US Biotechs che ha restituito 15.7 % nell'ultimo anno.

Rendimento vs Mercato: ORTX ha superato il mercato US che ha restituito 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is ORTX's price volatile compared to industry and market?
ORTX volatility
ORTX Average Weekly Movement	0.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: ORTX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di ORTX è diminuita da 16% a 1% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	166	Bobby Gaspar	www.orchard-tx.com

Orchard Therapeutics plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Orchard Therapeutics con la sua capitalizzazione di mercato?
ORTX statistiche fondamentali
Capitalizzazione di mercato	US$380.12m
Guadagni(TTM)	-US$72.92m
Ricavi(TTM)	US$21.84m

17.4x

Rapporto P/S

-5.2x

Rapporto P/E

ORTX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ORTX Conto economico (TTM)
Ricavi	US$21.84m
Costo del fatturato	US$79.52m
Profitto lordo	-US$57.68m
Altre spese	US$15.24m
Guadagni	-US$72.92m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-3.20
Margine lordo	-264.11%
Margine di profitto netto	-333.90%
Rapporto debito/patrimonio netto	31.9%

Come si è comportato ORTX nel lungo periodo?

Vedi performance storica e confronto

ORTX Panoramica delle azioni

Premi

Analisi del rischio

Orchard Therapeutics plc Concorrenti

NasdaqGM:ARTV

US$340.3m

NasdaqGM:FHTX

US$517.9m

NasdaqGS:ADAP

US$249.9m

NasdaqGM:ACIU

US$371.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Recent updates

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

New major risk - Financial position

Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy

Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023

Price target decreased by 25% to US$16.00

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

New major risk - Share price stability

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023

Consensus estimates of losses per share improve by 55%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 30%

Consensus EPS estimates upgraded to US$1.61 loss

Consensus EPS estimates upgraded to US$1.81 loss

Consensus revenue estimates decrease by 18%, EPS upgraded

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Price target decreased by 28% to US$21.60

Price target decreased by 8.7% to US$27.40

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Price target decreased to US$3.67

Insufficient new directors

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Consensus forecasts updated

Price target decreased to US$3.67

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Price target decreased to US$3.67

Price target decreased to US$4.00

Insufficient new directors

Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates increase by 37%

Price target decreased to US$8.64

Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD

Orchard Therapeutics: Shadow Of Former Glory

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.20 loss in 3Q 2020)

Price target decreased to US$10.31

Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

Consensus forecasts updated

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Consensus forecasts updated

Price target decreased to US$11.70

Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V.

Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Price target decreased to US$13.00